Eshel R - Search Results

1

Microenvironmental factors regulate Ly-6 A/E expression on PyV-transformed BALB/c 3T3 cells.

Eshel R, Firon M, Katz BZ, Sagi-Assif O, Aviram H, Witz IP. Eshel R, et al. Immunol Lett. 1995 Jan;44(2-3):209-12. doi: 10.1016/0165-2478(94)00216-e. Immunol Lett. 1995. PMID: 7797253

2

An association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype.

Katz BZ, Eshel R, Sagi-Assif O, Witz IP. Katz BZ, et al. Among authors: eshel r. Int J Cancer. 1994 Dec 1;59(5):684-91. doi: 10.1002/ijc.2910590517. Int J Cancer. 1994. PMID: 7960242

3

Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress.

Treister A, Sagi-Assif O, Meer M, Smorodinsky NI, Anavi R, Golan I, Meshel T, Kahana O, Eshel R, Katz BZ, Shevach E, Witz IP. Treister A, et al. Among authors: eshel r. Int J Cancer. 1998 Jul 17;77(2):306-13. doi: 10.1002/(sici)1097-0215(19980717)77:2<306::aid-ijc22>3.0.co;2-7. Int J Cancer. 1998. PMID: 9650569

4

Human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells.

Eshel R, Zanin A, Kapon D, Sagi-Assif O, Brakenhoff R, van Dongen G, Witz IP. Eshel R, et al. Int J Cancer. 2002 Apr 20;98(6):803-10. doi: 10.1002/ijc.10301. Int J Cancer. 2002. PMID: 11948455

5

Receptors involved in microenvironment-driven molecular evolution of cancer cells.

Eshel R, Neumark E, Sagi-Assif O, Witz IP. Eshel R, et al. Semin Cancer Biol. 2002 Apr;12(2):139-47. doi: 10.1006/scbi.2001.0422. Semin Cancer Biol. 2002. PMID: 12027586 Review.

6

The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells.

Eshel R, Zanin A, Sagi-Assif O, Meshel T, Smorodinsky NI, Dwir O, Alon R, Brakenhoff R, van Dongen G, Witz IP. Eshel R, et al. J Biol Chem. 2000 Apr 28;275(17):12833-40. doi: 10.1074/jbc.275.17.12833. J Biol Chem. 2000. PMID: 10777581 Free article.

7

The FX enzyme is a functional component of lymphocyte activation.

Eshel R, Besser M, Zanin A, Sagi-Assif O, Witz IP. Eshel R, et al. Cell Immunol. 2001 Nov 1;213(2):141-8. doi: 10.1006/cimm.2001.1872. Cell Immunol. 2001. PMID: 11831876

8

Leukomogenic factors downregulate heparanase expression in acute myeloid leukemia cells.

Eshel R, Ben-Zaken O, Vainas O, Nadir Y, Minucci S, Polliack A, Naparstek E, Vlodavsky I, Katz BZ. Eshel R, et al. Biochem Biophys Res Commun. 2005 Oct 7;335(4):1115-22. doi: 10.1016/j.bbrc.2005.08.004. Biochem Biophys Res Commun. 2005. PMID: 16112651

9

Involvement of heparanase in tumor progression and normal differentiation.

Vlodavsky I, Zcharia E, Goldshmidt O, Eshel R, Katz BZ, Minucci S, Kovalchuk O, Penco S, Pisano C, Naggi A, Casu B. Vlodavsky I, et al. Among authors: eshel r. Pathophysiol Haemost Thromb. 2003;33 Suppl 1:59-61. doi: 10.1159/000073296. Pathophysiol Haemost Thromb. 2003. PMID: 12955007 No abstract available.

10

Highly sensitive patient-specific real-time PCR SNP assay for chimerism monitoring after allogeneic stem cell transplantation.

Eshel R, Vainas O, Shpringer M, Naparstek E. Eshel R, et al. Lab Hematol. 2006;12(1):39-46. doi: 10.1532/LH96.05034. Lab Hematol. 2006. PMID: 16513545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters